Participant choices for return of genomic results in the eMERGE Network.
Hoell, C; Wynn, J; Rasmussen, LV; Marsolo, K; Aufox, SA; Chung, WK; Connolly, JJ; Freimuth, RR; Kochan, D; Hakonarson, H; et al.
Genetics in Medicine.
2020;
22:1821-1829.
Tertiary Pediatric Academic Institution's Experience With Intraoperative Neuromonitoring for Nonspinal Surgery in Children With Mucopolysaccharidosis, Based on a Novel Evidence-Based Care Algorithm.
Kandil, AI; Pettit, CS; Berry, LN; Busso, VO; Careskey, M; Chesnut, E; Buck, DW; Leslie, ND; Tamai, J; McAuliffe, JJ; et al.
Anesthesia and Analgesia.
2020;
130:1678-1684.
A comparison of clinical outcomes and transplant complications/morbidity with early (<4 months of age) versus late (~ 1 yr of age) hematopoietic stem cell transplant in sibling pairs with a diagnosis of MPS I (Hurler syndrome).
Wehmeyer, C; Mack, A; Bailey, L; Leslie, N; Prada, C.
Molecular Genetics and Metabolism.
2020;
129.
Clinical characteristics and genotypes in the ADVANCE baseline data set, a comprehensive cohort of US children and adolescents with Pompe disease.
Kishnani, PS; Gibson, JB; Gambello, MJ; Hillman, R; Stockton, DW; Kronn, D; Leslie, ND; Pena, LD M; Tanpaiboon, P; Day, JW; et al.
Genetics in Medicine.
2019;
21:2543-2551.
GAA variants and phenotypes among 1,079 patients with Pompe disease: Data from the Pompe Registry.
Reuser, AJ J; van der Ploeg, AT; Chien, YH; Llerena, J; Abbott, MA; Clemens, PR; Kimonis, VE; Leslie, N; Maruti, SS; Sanson, BJ; et al.
Human Mutation.
2019;
40:2146-2164.
Front Cover, Volume 40, Issue 11.
Reuser, AJ J; Chien, Y; Llerena, J; Abbott, M; Clemens, PR; Kimonis, VE; Leslie, N; Maruti, SS; Sanson, B; Araujo, R; et al.
Human Mutation.
2019;
40:i-i.
Expanding and Underscoring the Hepato-Encephalopathic Phenotype of QIL1/MIC13.
Russell, BE; Whaley, KG; Bove, KE; Labilloy, A; Lombardo, RC; Hopkin, RJ; Leslie, ND; Prada, C; Assouline, Z; Barcia, G; et al.
Hepatology.
2019;
70:1066-1070.
EMPOWERS: A phase 1/2 clinical trial of SB-318 ZFN-mediated in vivo human genome editing for treatment of MPS I (Hurler syndrome).
Harmatz, P; Lau, HA; Heldermon, C; Leslie, N; Foo, CW P; Vaidya, SA; Whitley, CB.
Molecular Genetics and Metabolism.
2019;
126.
Acquired ornithine transcarbamylase deficiency in pediatric and adolescent patients with fibrolamellar hepatocellular carcinoma.
Bartlett, AL; Leslie, ND; Gupta, A; Geller, JI.
Pediatric Blood and Cancer.
2018;
65.
Efficacy, safety profile, and immunogenicity of alglucosidase alfa produced at the 4,000-liter scale in US children and adolescents with Pompe disease: ADVANCE, a phase IV, open-label, prospective study.
Hahn, SH; Kronn, D; Leslie, ND; Pena, LD M; Tanpaiboon, P; Gambello, MJ; Gibson, JB; Hillman, R; Stockton, DW; Day, JW; et al.
Genetics in Medicine.
2018;
20:1284-1294.